How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.07. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM) , Dynavax Technologies (DVAX) , SCYNEXIS (SCYX) , VBI Vaccines (VBIV) , Viking Therapeutics (VKTX) , Selecta Biosciences (SELB) , Sorrento Therapeutics (SRNE) , Amarin (AMRN) , Vaxart (VXRT) and Agile Therapeutics (AGRX) .

When did PhaseBio Pharmaceuticals IPO?

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.

How do I buy shares of PhaseBio Pharmaceuticals?

Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:PHAS

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

→ Biden replacement revealed? (From Paradigm Press) (Ad)

Free PHAS Stock Alerts

Compare

Today's Range: N/A
50-Day Range: N/A
52-Week Range: N/A

Volume: N/A
Average Volume: 848,888 shs
Market Capitalization: $3.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Insider Trades SEC Filings Social Media Sustainability

Get PhaseBio Pharmaceuticals alerts:

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)

Click here to download your report

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Ad Darwin

Your Next Portfolio Star: Revealing 2024's Top Stock Pick

Click here to download your report

PHAS Stock News Headlines

December 14, 2023 | finance.yahoo.com

Velia Therapeutics Appoints Michael York as Chief Business Officer

June 5, 2023 | finance.yahoo.com

Alcami Announces CEO Transition

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

These sheets tell you the exact day you should consider buying a stock… And the exact day you should consider selling it… All based on TEN YEARS of historic data and trends. For example, like January 6th through the 12th with Apple… It’s gone up every single year for the last decade. Or like May 26th through June 11th with LULU… Again - it’s gone up every single year for the last decade. Then there’s July 1st through the 21st with Walmart… What happened to WMT?

May 12, 2023 | marketwatch.com

8-K: PhaseBio Pharmaceuticals Inc

March 31, 2023 | finanznachrichten.de

Absci Corporation: Absci Reports Fourth Quarter and Full Year 2022 Financial and Operating Results

March 31, 2023 | finanznachrichten.de

BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

March 31, 2023 | finance.yahoo.com

BioCryst Appoints Dr. Nancy Hutson as Chair of the Board

March 22, 2023 | marketwatch.com

Cardiomyopathy Medication Market Size and Forecast till 2031

April 19, 2024 | DTI (Ad)

Special FREE offer on stock hotsheets

February 28, 2023 | marketwatch.com

Cardiomyopathy Medication Market Emerging Demand and Drive Growth by 2028 with Top Countries Data

January 17, 2023 | benzinga.com

SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals

January 5, 2023 | bizjournals.com

Bankruptcy court approves PhaseBio's $32.9M asset transfer deal

November 8, 2022 | marketwatch.com

Bankrupt PhaseBio Identifies Chiesi as Lead Bidder for Bentracimab Assets

November 4, 2022 | benzinga.com

Short Volatility Alert: PhaseBio Pharmaceuticals, Inc.

November 2, 2022 | msn.com

Why Benefitfocus Shares Are Trading Higher By Around 48%? Here Are 64 Stocks Moving In Wednesday's Mid-Day Session

November 1, 2022 | msn.com

Why Goodyear Tire & Rubber Shares Are Trading Lower; Here Are 24 Stocks Moving Premarket

October 27, 2022 | benzinga.com

PhaseBio Pharmaceuticals 10% Owner Trades Company's Stock

October 25, 2022 | wsj.com

PhaseBio Files for Bankruptcy Following Blackstone-Backed Partner’s Lawsuit

October 25, 2022 | bizjournals.com

PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $100M

October 24, 2022 | nasdaq.com

PhaseBio Pharma Files For Chapter 11 Bankruptcy Protection

October 24, 2022 | finance.yahoo.com

PhaseBio Plans for Near-Term Sale Using Structured Process Through Chapter 11 of U.S. Bankruptcy Code

October 24, 2022 | finance.yahoo.com

PhaseBio files for bankruptcy, has a potential deal to sell its assets for up to $60M

October 24, 2022 | finance.yahoo.com

PhaseBio Files for Bankruptcy With Plans to Sell Assets

October 19, 2022 | bizjournals.com

Cash-strapped PhaseBio sued by drug development partner in dispute over experimental therapy

October 6, 2022 | finance.yahoo.com

PhaseBio Might Have To Return Global Rights To Its Lead Program

October 3, 2022 | finance.yahoo.com

Hypertension Clinical Trials Pipeline Analysis: 90+ Companies are Working to Improve the Treatment Space | DelveInsight

September 29, 2022 | finance.yahoo.com

Why an East Bay company wants control of its partner's blood thinner antidote

See More Headlines

Receive PHAS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/10/2021
Today: 4/19/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:PHAS
CUSIP: N/A
CIK: 1169245
Web: www.phasebio.com
Phone: (610) 981-6500
Fax: N/A
Employees: 60
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($2.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-131,070,000.00
Net Margins: -12,572.13%
Pretax Margin: -12,572.13%
Return on Equity: N/A
Return on Assets: -174.38%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.47
Quick Ratio: 0.47

Sales & Book Value

Annual Sales: $818,000.00
Price / Sales: 0.00
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($1.93) per share
Price / Book: N/A

Miscellaneous

Outstanding Shares: 49,858,000
Free Float: 44,922,000
Market Cap: $3.50 million
Optionable: Not Optionable
Beta: 2.57

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Jonathan P. Mow
Chief Executive Officer & Director
John P. Sharp
Chief Financial Officer
John S. Lee
Chief Medical Officer
Kristopher L. Hanson
Secretary, Senior VP & General Counsel
Susan E. Arnold
Senior Vice President-Technical Operations

Key Competitors

View All Competitors

PHAS Stock Analysis - Frequently Asked Questions

How were PhaseBio Pharmaceuticals' earnings last quarter?: PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.07. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million.
What other stocks do shareholders of PhaseBio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other PhaseBio Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Dynavax Technologies (DVAX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Sorrento Therapeutics (SRNE), Amarin (AMRN), Vaxart (VXRT) and Agile Therapeutics (AGRX).
When did PhaseBio Pharmaceuticals IPO?: PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager.
How do I buy shares of PhaseBio Pharmaceuticals?: Shares of PHAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PHAS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS)

PHAS Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

PHAS Stock Analysis - Frequently Asked Questions

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info